Literature DB >> 20184973

Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle.

Chloe L Thio, David L Thomas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20184973      PMCID： PMC3805379          DOI： 10.1053/j.gastro.2010.02.033

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  30 in total

1.  Common genetic variation and human traits.

Authors:  David B Goldstein
Journal:  N Engl J Med       Date:  2009-04-15       Impact factor: 91.245

Review 2.  Prioritizing GWAS results: A review of statistical methods and recommendations for their application.

Authors:  Rita M Cantor; Kenneth Lange; Janet S Sinsheimer
Journal:  Am J Hum Genet       Date:  2010-01       Impact factor: 11.025

3.  Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.

Authors:  Maribel Rodriguez-Torres; Lennox J Jeffers; Muhammad Y Sheikh; Lorenzo Rossaro; Victor Ankoma-Sey; Fayez M Hamzeh; Paul Martin
Journal:  N Engl J Med       Date:  2009-01-15       Impact factor: 91.245

4.  Regulatory polymorphisms in the interleukin-18 promoter are associated with hepatitis C virus clearance.

Authors:  Ping An; Chloe L Thio; Gregory D Kirk; Sharyne Donfield; James J Goedert; Cheryl A Winkler
Journal:  J Infect Dis       Date:  2008-10-15       Impact factor: 5.226

5.  Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family.

Authors:  Hans Henrik Gad; Christoffer Dellgren; Ole J Hamming; Susanne Vends; Søren R Paludan; Rune Hartmann
Journal:  J Biol Chem       Date:  2009-05-20       Impact factor: 5.157

6.  Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.

Authors:  Tania Mara Welzel; Timothy R Morgan; Herbert L Bonkovsky; Deepa Naishadham; Ruth M Pfeiffer; Elizabeth C Wright; Amy A Hutchinson; Andrew T Crenshaw; Arman Bashirova; Mary Carrington; Myhanh Dotrang; Richard K Sterling; Karen L Lindsay; Robert J Fontana; William M Lee; Adrian M Di Bisceglie; Marc G Ghany; David R Gretch; Stephen J Chanock; Raymond T Chung; Thomas R O'Brien
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

7.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

8.  Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C.

Authors:  Yasuhito Tanaka; Nao Nishida; Masaya Sugiyama; Masayuki Kurosaki; Kentaro Matsuura; Naoya Sakamoto; Mina Nakagawa; Masaaki Korenaga; Keisuke Hino; Shuhei Hige; Yoshito Ito; Eiji Mita; Eiji Tanaka; Satoshi Mochida; Yoshikazu Murawaki; Masao Honda; Akito Sakai; Yoichi Hiasa; Shuhei Nishiguchi; Asako Koike; Isao Sakaida; Masatoshi Imamura; Kiyoaki Ito; Koji Yano; Naohiko Masaki; Fuminaka Sugauchi; Namiki Izumi; Katsushi Tokunaga; Masashi Mizokami
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

9.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

10.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962
View more
  9 in total

1.  Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response.

Authors:  Roberta Melis; Christiane Fauron; Gwendolyn McMillin; Elaine Lyon; Brian Shirts; Lindsey M Hubley; Patricia R Slev
Journal:  J Mol Diagn       Date:  2011-05-14       Impact factor: 5.568

2.  Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.

Authors:  Mariko Kobayashi; Fumitaka Suzuki; Norio Akuta; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Yusuke Kawamura; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Kazuaki Chayama; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2012-03-23       Impact factor: 7.527

3.  Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients.

Authors:  Evaldo Stanislau Affonso de Araujo; Harel Dahari; Scott J Cotler; Thomas J Layden; Avidan U Neumann; Carlos Eduardo Melo; Antonio Alci Barone
Journal:  J Acquir Immune Defic Syndr       Date:  2011-02-01       Impact factor: 3.731

Review 4.  IL28B and the control of hepatitis C virus infection.

Authors:  Ashwin Balagopal; David L Thomas; Chloe L Thio
Journal:  Gastroenterology       Date:  2010-10-13       Impact factor: 22.682

Review 5.  Mechanisms of HCV-induced liver cancer: what did we learn from in vitro and animal studies?

Authors:  Ivan Rusyn; Stanley M Lemon
Journal:  Cancer Lett       Date:  2013-07-18       Impact factor: 8.679

6.  IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy.

Authors:  Barham K Abu Dayyeh; Namrata Gupta; Kenneth E Sherman; Paul I W de Bakker; Raymond T Chung
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

7.  IL28B gene polymorphism SNP rs8099917 genotype GG is associated with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in HTLV-1 carriers.

Authors:  Tatiane Assone; Fernando Vieira de Souza; Karen Oliveira Gaester; Luiz Augusto Marcondes Fonseca; Olinda do Carmo Luiz; Fernanda Malta; João Renato Rebello Pinho; Fernanda de Toledo Gonçalves; Alberto Jose da Silva Duarte; Augusto Cesar Penalva de Oliveira; Jorge Casseb
Journal:  PLoS Negl Trop Dis       Date:  2014-09-18

Review 8.  Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies.

Authors:  Chun-Hsiang Wang; Yuchi Hwang; Eugene Lin
Journal:  J Exp Pharmacol       Date:  2010-06-23

9.  Combined Effects of 2 Interleukin 28B Polymorphisms on the Therapeutic Outcome of Hepatitis C Patients With Circulating Cryoglobulins.

Authors:  Francesco Bellanti; Gianfranco Lauletta; Rosanna Villani; Maria Rosaria Lipsi; Maria Iole Natalicchio; Domenico Sansonno; Gianluigi Vendemiale; Gaetano Serviddio
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.